Immunocore chief executive cements role at Adaptimmune
pharmafile | March 27, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Adaptimmune, immunocore, noble
Biotech firm Adaptimmune has confirmed the full-time appointment of James Noble as its chief executive.
Noble has been chief executive of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as chief executive of sister company, Immunocore.
He will remain on the board at Immunocore as a non-executive director. Dr Jonathan Knowles who is currently the executive chairman of both Adaptimmune and Immunocore, will serve as acting chief executive of Immunocore until the company finds a permanent replacement.
The origins of Adaptimmune and Immunocore go back to 1999 when a novel T cell receptor technology was spun out of the University of Oxford into a company named Avidex Limited, where Noble was chief executive until its acquisition by MediGene in 2006.
Noble says: “It has been a privilege to oversee the successful expansion of Immunocore through its partnerships and I am delighted to be able to focus on Adaptimmune going forward. I look forward to building the company up over the coming years.”
Knowles adds: “It is a real pleasure to be associated with the success of Immunocore and Adaptimmune in parallel, and I would like to acknowledge the very significant achievement of James in leading both companies up to this point. I am delighted that James has agreed to take on the full-time CEO position at Adaptimmune while remaining on the Immunocore board as a non-executive director.”
Related Content
Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour
Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given …
AstraZeneca loses two senior executives as biotechs appoint new CEOs
Two of AstraZeneca’s senior executives have been poached by the biotech firms Ironwood Pharmaceuticals and …
Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial
Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a …
